ID   JK-6L
AC   CVCL_0C41
SY   JK6L; JK-6 IL6-independent
DR   cancercelllines; CVCL_0C41
DR   Cosmic; 2081386
DR   DSMZ; ACC-860
DR   DSMZCellDive; ACC-860
DR   Wikidata; Q54898960
RX   CelloPub=CLPUB00604;
RX   PubMed=17308121;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=19621390;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Characteristics: Produces IgG kappa.
CC   Characteristics: Compared to the parent cell line, it is no longer IL6 dependent.
CC   Doubling time: ~48 hours (DSMZ=ACC-860).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (DSMZ=ACC-860).
CC   Sequence variation: Mutation; HGNC; 7795; NFKB2; Simple; p.Arg725Glufs*18 (c.2171delC); Zygosity=Homozygous (PubMed=17692805).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Tyr64Asp (c.190T>G); dbSNP=rs752508313; Zygosity=Unspecified (DSMZ=ACC-860).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Caution: Indicated as JK-6 in DSMZ, but the original JK-6 was IL-dependent and the IL-6 independent subline was called JK-6L (PubMed=19621390).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ=ACC-860
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 12,13,16
ST   D19S433: 13,14
ST   D21S11: 31.2,32
ST   D2S1338: 16,17
ST   D3S1358: 16,17
ST   D5S818: 13
ST   D7S820: 8,12
ST   D8S1179: 10,14
ST   FGA: 19,23
ST   Penta D: 12
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M534 ! JK-6
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 02-05-24; Version: 14
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   PubMed=17308121; DOI=10.1158/0008-5472.CAN-06-2258;
RA   Meister S., Schubert U., Neubert K., Herrmann K., Burger R.,
RA   Gramatzki M., Hahn S., Schreiber S., Wilhelm S., Herrmann M.,
RA   Jack H.-M., Voll R.E.;
RT   "Extensive immunoglobulin production sensitizes myeloma cells for
RT   proteasome inhibition.";
RL   Cancer Res. 67:1783-1792(2007).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=19621390; DOI=10.1002/ijc.24758;
RA   Guenther A., Gordon S., Tiemann M., Burger R., Bakker F., Green J.R.,
RA   Baum W., Roelofs A.J., Rogers M.J., Gramatzki M.;
RT   "The bisphosphonate zoledronic acid has antimyeloma activity in vivo
RT   by inhibition of protein prenylation.";
RL   Int. J. Cancer 126:239-246(2010).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//